Filing Flows › Health Care › Oncotelic Therapeutics (OTLC)
Oncotelic Therapeutics (OTLC) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Oncotelic Therapeutics (OTLC) Q2 2026 earnings results →
Q2 2026 136¢ of every $1 of revenue kept as net profit · operating margin -337.4%
Oncotelic Therapeutics made $250K in Q2 2026. Operating margin -337.4%, net earnings $341K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $250K in Q2 2026.
Operating costs exceeded revenue by $844K, an operating margin of -337.4%. Net earnings were $388K ($341K including minority interests, which bore $47K of losses). The effective tax rate was 0.0%. Non-operating items added $1.2M, 347% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$92K. Non-cash charges added back $730K of share-based compensation. Working capital and other items used $1.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $250K | — | -337.4% | $341K | −$92K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Oncotelic Therapeutics
Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc.) (“ Oncotelic ”), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic conducts business activities through Oncotelic and its wholly-owned subsidiaries, Oncotelic, Inc., a Delaware corporation, PointR Data, Inc. (“ PointR ”), a Delaware corporation, Pet2DAO, Inc., a Delaware corporation; and EdgePoint AI, Inc. (“ Edgepoint” ), a Delaware Corporation for which there are non-controlling interests, (Oncotelic, Oncotelic Inc., PointR, Pet2DAO and Edgepoint are collectively called the “ Company ” or “ We ”).
In its own words, from its 10-K, filed Apr 15, 2026.
Oncotelic Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: -337.4% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| OTLC Oncotelic Therapeutics | Q2 2026 | $250K | — | -337.4% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Oncotelic Therapeutics 10-Q on SEC EDGAR · CIK 908259 · Pharmaceutical Preparations
More on OTLC
History
Every quarter: Q2 2026 results